Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas | Zendy

Dongyun Zhang | Zendy; Jennifer Sue An Way | Zendy; Xinhai Zhang | Zendy; Sergey Mareninov | Zendy; Marvin Bergsneider | Zendy; Marilene B. Wang | Zendy; William H. Yong | Zendy; Anthony P. Heaney | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas

Author(s) -

Dongyun Zhang,

Jennifer Sue An Way,

Xinhai Zhang,

Sergey Mareninov,

Marvin Bergsneider,

Marilene B. Wang,

William H. Yong,

Anthony P. Heaney

Publication year - 2019

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-02461

Subject(s) - cabergoline , everolimus , pi3k/akt/mtor pathway , neuroendocrine tumors , medicine , protein kinase b , prolactin , endocrinology , pituitary tumors , cancer research , biology , signal transduction , biochemistry , hormone

Aggressive prolactin (PRL)-secreting pituitary adenomas that are resistant to conventional therapy with dopamine agonists, surgery, and radiation pose a therapeutic challenge. The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved to treat neuroendocrine tumors (NETs), and cotreatment with the somatostatin receptor ligand octreotide improved median progression-free survival in patients with metastatic pancreatic NETs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research